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1. Introduction 
Oral squamous cell carcinoma (OSCC) is the most common head and neck cancers, and rank 
as one of the top ten cancers worldwide. More worrying is that the incidence of oral cancer 
appears to be increasing in many parts of the world. OSCC is characterized by a high degree 
of local invasiveness and a high rate of metastasis to the cervical lymph nodes. Survival of 
patients with OSCC has not improved in the last 40 years, despite recent advances in 
surgical procedures and the availability of new chemotherapeutic agents. In addition, 
surgical resection results in significant functional and cosmetic defects; therefore, it is 
important to develop conservative therapeutics, whereupon identification of markers 
representing OSCC aggressiveness would be worthwhile to decide the most suitable 
treatment for each patient from therapeutic options. 
Given that the head and neck region is an environment challenged by a large variety of 
insults, including pathogens, foods, and chemicals, the relationship between cancer cells and 
inflammatory stroma might be of particular importance for arising malignancies there. The 
microenvironment plays a critical role in tumor initiation and progression, and may provide 
attractive therapeutic targets. In fact, it affects not only tumor growth, invasion, and 
metastasis, but also drug metabolism and accessibility; hence the role of stromal elements 
has been extensively investigated at a molecular level. Although host-tumor interactions are 
two-way communications between cancer cells and stroma; however, knowledge about the 
cancer cell properties specifically evoked in the microenvironment is still limited. 
In this review, we provide an overview of the literatures regarding “functional biomarkers” 
of OSCCs, introduce our recent discovery of the in vivo-specific maker, and discuss 
significance of these factors in diagnostic and clinical implication.  
2. Cellular biomarkers in OSCC 
Major cellular biomarkers correlated with the clinical outcome of OSCC have been reported, 
which were refined with a focus on the relationship between prognostic or survival 
parameters of OSCC patients and their expression levels, mainly using 
immunohistochemistry (Oliveira & Ribeiro-Silva, 2011). The biomarkers could be classified 
into five groups based on their biological functions: 1) cell cycle progression and 
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proliferation; 2) tumor suppression and apoptosis; 3) hypoxia; 4) angiogenesis; and 5) cell 
adhesion and matrix degradation. 
2.1 Cell cycle progression and proliferation biomarkers 
Several biomarkers belonging to this group have been identified: a family of epidermal 
growth factor receptors (EGFRs); cyclin D1; cyclin B1; Ki-67; proliferating cell nuclear 
antigen (PCNA); and Akt1. The EGFR family includes four members: HER-1 (EGFR, ErbB1), 
HER-2 (neu/ErbB2), HER-3 (ErbB3), and HER-4 (ErbB4). EGFR activation, as its name 
indicates, can augment the malignant potential of epithelial cells (LaCasse et al., 2008), and 
the overexpression correlates with poor prognosis in OSCC patients (Agra et al., 2008; 
Laimer et al., 2007; Silva et al., 2008, 2009). Cyclin proteins are key regulators of cell cycle 
progression. Cyclin D1 amplification is frequently detected as molecular alterations in 
OSCC and other head and neck cancers (Yu et al., 2005). There is a significant association 
between the combined expression of EGFR, cyclin D1, and p53 and an unfavorable overall 
survival in OSCC patients (Shiraki et al., 2005). Cyclin B1 is useful in predicting occult 
cervical lymph-node metastasis in OSCC (Harada et al., 2006). Ki-67 and PCNA are well-
established cell proliferation markers, and Ki-67 expression increases sharply in early OSCC, 
but significantly decreases during disease progression (Derka et al., 2006), while that of 
PCNA was not significantly associated with the survival (Kim et al., 2007; Lim et al., 2005; 
Myoung et al., 2006). Akt plays a pivotal role in cell survival and proliferation. 
Overexpression of Akt is a significant indicator for predicting poor prognosis in OSCC 
patients (Lim et al., 2005). 
2.2 Tumor suppression and apoptosis biomarkers 
Five subsets of biomarkers were identified in this group: p53/p63, p21/p27, Bcl-2 family 
members, the retinoblastoma (Rb) protein, and Survivin. The tumor suppressor p53 is one of 
the most studied biomarkers in OSCC, as well as in other malignancies. The high expression 
of p53 is especially detected at advanced stages of carcinogenesis, and is also associated with 
a poor prognosis (Oliveira et al, 2007a, 2007b, 2008), while the clinical significance of that of 
p63, a p53 homologue, remains controversial (Oliveira et al., 2007a, 2007b; Lo Muzio et al., 
2005a, 2007). Mutation of p53 occurs in 50% of OSCC cases (Ogden et al., 1992, 1996), which 
might be pertinent to consequent overexpression of this molecule. p21waf1/cip1 and p27Kip1 
play an important function in regulating cell cycle progression through the inhibitory action 
on cyclin-dependent kinases. There are controversial findings concerning the clinical 
outcome of p21waf1/cip1-positive OSCCs (Fillies et al., 2007; Nemes et al., 2005), whereas no 
significant association between p27Kip1 expression and OSCC prognosis has been identified 
(Fillies et al., 2007). Bcl-2 family members include both anti- and pro-apoptotic proteins, and 
thereby regulate apoptosis either positively or negatively through their balance (Camisasca 
et al., 2009). The survival rate of patients with Bcl-2-negative and Bax-positive OSCC tumors 
was significantly higher than those with other expression profiles of these molecules (Kato 
et al., 2008; Zhang et al., 2009). The Rb pathway plays a crucial role in regulating cell cycle 
progression. OSCCs lacking Rb indeed display aggressiveness with the poor prognosis (Soni 
et al., 2005). Survivin is an inhibitor of apoptosis and overexpressed in most of OSCCs, 
indicating a potential biomarker of aggressiveness and invasiveness (Lippert et al., 2007; Lo 
Muzio et al., 2005b). 
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2.3 Hypoxia biomarkers 
Four hypoxia-related biomarkers have been reported as putative prognostic parameters: 
hypoxia inducible factor 1 (HIF-1); carbonic anhydrase IX (CA IX); glucose transporter 
1 (GLUT-1); and erythropoietin receptor (EPOR). In hypoxic environments, stabilized 
HIF-1 induces the transactivation of more than 70 genes, including vascular endothelial 
growth factor (VEGF), involved in hypoxia adaptation and/or reversion (Fillies et al., 
2005; Liu et al., 2008). The diffuse overexpression of HIF-1 had been associated with a 
good prognosis in OSCC patients (Fillies et al., 2005), whereas recently the opposite 
evidences have been reported (Lin et al., 2008; Liu et al., 2008). The latter finding might be 
supported by the ability of HIF-1in inducing VEGF and promoting invasive phenotypes. 
Indeed, HIF family members are implicated in epithelial mesenchymal transition (EMT) of 
cancer cells (Yang MH., 2008). CA IX, a member of HIF-1-dependent CA family, is a 
transmembrane glycoprotein involved in pH homeostasis (Sakata et al., 2008). 
Overexpression of CA IX has been shown to significantly associate with recurrence and 
worse survival in OSCC patients (Choi et al., 2008). GLUT is also regulated via the HIF-1 
pathway, mediates cellular glucose uptake, and namely represents as an endogenous 
marker of hypoxia (Kunkel et al., 2007). There is evidence that GLUT-1 is associated with 
aggressiveness in OSCC (Jonathan et al., 2006). Erythropoietin (EPO) is a glycoprotein 
hormone and synthesized in the kidneys in response to hypoxemia, and OSCC has been 
known to express its cognate receptor EPOR (Arcasoy et al., 2005). High expression of 
EPOR can be associated with a significantly worse prognosis in patients with oral tongue 
squamous cell carcinoma (Roh et al., 2009). 
2.4 Angiogenesis biomarkers 
Four angiogenic biomarkers were identified as possible prognostic parameters: VEGF; 
endoglin (CD105); CD34; and Eph receptor tyrosine kinases. VEGF functions mainly as an 
angiogenic cytokine that promotes proliferation, differentiation, and migration of vascular 
endothelial cells. Therefore, it should be ideally discussed in the section of humoral factors, 
but we would like to state here due to the importance of its intracellular transcriptional 
regulation by HIF-1. The patients with VEGF-positive tumors have significantly poor 
survival (Chien et al., 2006; Shao et al., 2008). Despite the established role of VEGF for 
angiogenesis, a recent study showed that an anti-VEGF antibody failed to interrupt the 
connection between OSCC and endothelial cells (Yamada et al., 2011); hence VEGF functions 
in tumor progression, other than angiogenesis, have yet to be determined. CD105, a 
regulatory component of the TGF- receptor complex, can modulate angiogenesis. High 
expression of CD105 in primary OSCC may identify patients at risk of the recurrence with 
worse prognosis (Chuang et al., 2006). In addition, the existence of penetrating vessels 
within tumor nests, endothelial cells of which can be visualized by CD34 staining, was 
significantly associated with risk of cervical lymph node metastasis (Kademani et al., 2009). 
The Eph receptors and their membrane-anchored ephrin ligands can stimulate invasive 
behavior in a tumor through a cell-cell communication system capable of bi-directional 
signaling, thereby promoting a more aggressive and metastatic phenotype (Campbell et al., 
2008; Wimmer-Kleikamp et al., 2005). High expression of EphA2 was associated with a poor 
survival in tongue SCC patients (Shao et al., 2008). 
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Category (section no.)
Status Cellular/clinical characteristics 
 Pathways (section 
no.) 
  Biomarker 
Cellular Biomarker (2)
 Cell cycle promotion and proliferation (2.1)
  EGFR overexpression poor prognosis
   Cyclin D1 amplification unfavorable overall survival 
    Cyclin B1 overexpression in cytoplasm cervical lymph node metastasis 
    Ki-67 increase (early), decrease (late) poor overall survival
    PCNA positive no significant association on survival 
    Akt overexpression poor prognosis
  Tumor suppression and apoptosis (2.2)
  p53 overexpression, mutation poor prognosis
    p63 positive controversial
    p21 overexpression controversial
    p27 overexpression no significant association on survival 
    Bcl-2 negative higher survival
    Bax positive higher survival
    Rb loss malignant conversion, poor prognosis 
    survivin overexpression aggressive and invasive
  Hypoxia (2.3) 
  HIF-1 diffuse overexpression good prognosis or controversial 
    CA IX overexpression recurrence with worse survival 
    GLUT-1 high expression metastasis, worse overall survival 
    EPOR high expression worse prognosis
  Angiogenesis (2.4)
  VEGF positive poor prognosis
    CD105 high expression recurrence with worse prognosis 
    CD34 positive within tumor nests cervical lymph node metastasis 
    Eph A2 high expression poor survival 
  Cell adhesion and matrix degradation (2.5)
  MMP-7,-9, -13, -14 positive poor prognosis
    CD44 irregular cytoplasmic staining poor overall survival
    E-cadherin downregulation EMT, worse prognosis
    N-cadherin upregulation EMT
    - and -catenin positive poor prognosis
    versican overexpression in stroma unfavorable outcome
Humoral Biomarker (3)
 Parathyroid hormone-related protein (3.1)
  PTHrP high expression malignant conversion
 Endothelins and their receptors (3.2)
  Endothelins (ETs) overexpression tumor growth and progression 
    ETAR, ETBR overexpression tumor growth and progression 
  Inflammatory Cytokines and Chemokines (3.3)
  Interleukin (IL)-6 high expression tolerance to immune system 
   IL-8 high expression controversial
   TNF- high expression controversial
   CXCL13 high expression tumor development and progression 
In vivo specific Biomarker (4)
 Receptor activator of NF-B ligand
   RANKL high expression in vivo tumor development and progression 
Table 1. Molecular biomarkers and its correlation with cellular or clinical characteristics. 
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2.5 Cell adhesion and matrix degradation biomarkers 
Five classes of matrix degradation- and cell adhesion-related molecules were identified as 
putative prognostic biomarkers associated with OSCC: matrix metalloproteinases (MMPs), 
CD44, cadherins, catenins, and versican. The MMPs are a family of proteases, highly expressed 
by invasive tumor cells and the adjacent stroma, and essential for ECM degradation (de 
Vicente et al., 2005). Of over 20 known members of MMPs, expression of MMP-7, -9, -13, and -
14 (MT1-MMP) were significantly associated with poor prognosis of OSCC patients (De 
Vicente et al., 2005, 2007; Luukkaa et al., 2006). The CD44 family is widely expressed 
transmembrane glycoproteins that bind to hyaluronic acid, growth factors, and ECM proteins, 
regulating cell migration and adhesion (Georgolios et al., 2006). In contrast to strong 
membranous staining in normal squamous cell epithelium, the irregular cytoplasmic staining 
of CD44 in OSCC has been shown to correlates with poor disease-free and overall survivals 
(Kosunen et al., 2007). Cadherins are a family of transmembrane glycoproteins involved in 
cell-cell adhesion (Munoz-Guerra et al., 2005). In most epithelial cells, the intracellular domain 
of E-cadherin binds to catenins, forming the cadherin-catenin complex involved in the 
intracellular transduction of cell-to-cell contact signals. The reduced expression of E-cadherin, 
frequently concomitant with N-cadherin upregulation, leads to loss of cell-cell adhesion and 
acquisition of the mesenchymal phenotype (i.e. EMT), which plays an important role in tumor 
invasion and dissemination (Lyons et al., 2007). Accordingly, a decrease in the expression of - 
and -catenins can also predict poor prognosis of OSCC (Ueda et al., 2006). Versican is a major 
proteoglycan of the ECMs, and its overexpression was observed in diverse tumors. This 
molecule plays an essential role in tumor growth by repressing cell adhesion, stimulating cell 
proliferation and migration, and regulating angiogenesis (Rahmani et al., 2006). High stromal 
versican expression in OSCC specimens is an independent predictor for an unfavorable 
prognosis (Pukkila et al., 2007). 
3. Humoral biomarkers in OSCC 
Given that the significance of the microenvironment for OSCC initiation and/or promotion 
has been shown, as mentioned above, humoral factors that correlate with clinical features 
would be of particular important. VEGF may serve as a prototype molecule bridging 
between cancer cells and stromal component, namely endothelial cells as described (see 2.4). 
In this section, humoral biomarkers are enumerated irrespective of their source and their 
mode of action, para- or autocrine. 
3.1 Parathyroid hormone-related protein (PTHrP) 
PTHrP was originally identified as a major factor responsible for humoral hypercalcemia in 
malignancies (Burtis et al., 1990), and acts as a stimulator of osteoclastic bone resorption 
(Liao & McCauley, 2006). Therefore, plasma PTHrP level can be a predictor of existence of 
bone metastatic lesions in a wide range of tumors. PTHrP produced by cancer cells 
promotes malignant conversion (increased cell proliferation, survival, adhesion, migration, 
and invasion) of breast, colon, and prostate cancers (Shen et al., 2004), as well as OSCC 
(Nomura et al., 2007). Because OSCC expresses the PTH/PTHrP receptor PTH1R, its 
mechanism of action is in a paracrine or autocrine manner (Yamada et al., 2008). It is 
noteworthy that the expression level of PTHrP is regulated by downstream signaling of 
EGFR, another class of biomarker for malignant potential of OSCC (see 2.1). In addition, a 
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recently developed, rapid screening system identifies PTHrP as one of the validated 
predictors for OSCC (Ziober et al., 2006). 
3.2 Endothelins and their receptors as biomarkers in OSCC 
Hoffmann et al. recently reported novel functional biomarkers in OSCC, endothelin (ET) 
and its receptor, which are overexpressed in OSCC (Hoffmann et al., 2010). ETs comprise a 
family of three small peptides: ET-1, ET-2, and ET-3 (Yanagisawa et al, 1988; Levin, 1995). 
ET-1 is expressed primarily in endothelial cells, and ET-2 is in the kidneys and the intestine, 
whereas ET-3 is found mainly in the brain (Levin, 1995). ETs exert their effects by binding to 
cell-surface receptors, namely ET-A (ETAR) and ET-B (ETBR). Both receptors belong to the G-
protein-coupled receptor super-family (Levin, 1995; Kusserow et al., 2004; Motte et al, 2006; 
Bhalla et al., 2009). ETAR binds ET-1 with 10-times greater affinity than ET-3, whereas ETBR 
binds all three ETs with similar affinity. In general, most ET-1 functions are therefore 
mediated by interaction with ETAR (Guise et al., 2003). 
ET-1, ETAR, and ETBR are overexpressed in OSCC, in which ET-1 acts as a survival factor to 
induce proliferation via ETAR and ETBR (Awano et al., 2006). Schmidt et al. demonstrated a 
significant elevation in the levels of ET-1 in HSC-3 cells (Schmidt et al, 2007), a lineage 
obtained from human OSCC. ETAR activation by ET-1 largely contributes to tumor growth 
and progression through induction of cell proliferation, survival, angiogenesis, and metastatic 
spread, thus indicating that ETAR antagonism might improve cancer treatment (Rosano et al., 
2006; Nelson et al, 2003). ET-1 can also modulate tumor angiogenesis through induction of 
VEGF, which is accounted for by an increase in HIF-1 level by ETAR activation (Bagnato et al, 
2002). Besides their anti-angiogenic effect, ET receptor antagonists can also prevent the 
production of MMPs from macrophages (Grimshaw, 2007). Taken together, it is tempting to 
infer that blocking ET receptors, especially ETAR, might be a useful alternative as an adjuvant 
treatment of OSCC. Nevertheless, whether ET antagonists provide significant clinical benefit 
for patients with OSCC is a vital and controversial issue. In several clinical trials of metastatic 
castration-resistant prostate cancer patients, atrasentan, a competitive inhibitor of ET-1, did not 
improve the primary or secondary endpoint (Carducci, 2007; Nelson, 2008). Similar results 
have been obtained in other studies using a different ET antagonist zibotentan. Therefore, 
results of adequate, long-term clinical trials for OSCC are awaited. 
3.3 Inflammatory cytokines and chemokines 
Given the specific property of the oral cavity that is always challenged by a large variety of 
insults, including pathogens, foods, and chemicals, chronic inflammation and its molecular 
components such as cytokines or chemokines would be particular important for the 
development and progression of OSCC. In fact, several cytokines and chemokines are 
identified as biomarker of OSCC. 
Interleukin (IL)-6 and IL-8 have been implicated as potential biomarkers for OSCC. (St John 
et al., 2004). When these cytokines are expressed together with VEGF, OSCC has been 
shown to acquire resistance in a manner dependent on immune effectors (Teruel et al., 
2008). In addition, the concentration of saliva IL-6 in OSCC patients are significantly higher 
than that of control group, whereas results regarding IL-8 and tumor necrosis factor- are 
controversial (SahebJamee et al., 2008). 
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Chemokines are also implicated in tumor progression and metastasis of OSCC (Krieg & 
Boyman, 2008). More recently, gene expression profiling studies implicated chemokine 
ligand-13 (CXCL13) in OSCC tumor development and progression (Ziober et al., 2006). 
CXCL13 (BCA-1) that binds monogamously to the CXCR5 receptor was originally 
discovered to facilitate B-cell chemotaxis (Legler et al., 1998). CXCL13 can upregulate 
receptor activator of NF-B ligand (RANKL), a member of the tumor necrosis factor family 
critical for osteoclastogenesis (Hsu et al., 1999), through activation of c-Jun N terminus 
kinase and nuclear factor of activated T cells (NFAT)-4, implicating CXCL13 as a potential 
biomarker to predict OSCC bone invasion or osteolysis (Yuvaraj et al., 2009). 
4. In vivo-specific biomarkers — Lessons from RANKL 
Survival of patients with OSCC has not improved over the past few decades, despite recent 
advances in the treatments. One of the fundamental factors explaining the poor outcome is 
that a great proportion of oral cancers are diagnosed at advanced stages. In addition, 
surgical resection results in significant functional and cosmetic defects. Therefore, it is 
important to develop biomarkers for early diagnosis, as well as for the prediction of disease 
progression and/or aggressiveness to decide the most suitable treatment for each patient 
from therapeutic options. These facts have prompted molecular exploration for novel 
markers, and indeed lead to the discovery of manifold biomarkers, as described in the 
previous sections. 
Meanwhile, if a marker were functional in tumorigenesis, aggressiveness, or progression, it 
can be a plausible therapeutic target. As far as now, most markers have been identified 
because of their high expression in tumor tissues, evaluated by immunohistochemistry, and 
the significance are evaluated by comparison with clinical course of the patients, followed 
by functional analysis in vitro. However, given the specific feature of the oral cavity that is 
an environment challenged by a large variety of insults, including pathogens, foods, and 
chemicals, the molecules exert their functions in vivo would be more preferable. 
We have recently identified the osteoclastic cytokine RANKL as a marker for invasive and 
aggressive OSCC with its molecular function as an EMT and angiogenesis inducer (Yamada et 
al., 2011). Of particular interest is that both RANKL expression and function solely depend on 
the microenvironment; neither its high expression nor function, as the EMT inducer could not 
be reproduced in vitro. In other word, it is not necessarily enough to explore molecular 
functions only using in vitro settings. In the latter part of this review, we highlight the story of 
how RANKL is characterized as an in vivo-specific biomarker with the experimental 
procedures used, so that such attractive and valuable candidates for biomarker would not be 
abandoned because of the absence of in vitro-experimental evidence, as hypothesized 
4.1 High expression of RANKL in in vivo OSCC but not in cell lines 
We initially probed bone invasion-related factors in OSCC, and indeed reported that PTHrP 
is expressed in OSCC and enhances the malignant potential of OSCC (Yamada et al., 2008). 
We therefore hypothesized that PTHrP induces the expression of RANKL in a manner 
analogous to osteoblasts (Leibbrandt & Penninger, 2008; Mundy, 2002; Roodman, 2004), and 
examined the expression of RANKL mRNA and protein by quantitative RT-PCR and 
immunohistochemistry, respectively, in 20 human OSCC samples, including those in the 
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tongue and the gingiva. In all cases, high expression (from 6 to 123-fold) was observed 
compared to human control gingival fibroblast (Figure 1A), and the expression level of 
RANKL was positively correlated with the histological grading of differentiation and 
invasive histological architecture based on Yamamoto-Kohama classification (Yamamoto et 
al., 1983). In addition, abundant RANKL protein was observed in atypical cancer cells 
diffusely invaded into surrounding tissues. Nevertheless, none of the tested OSCC cell lines 
displayed such abundant RANKL expression as that observed in vivo. In particular, cell lines 
established from poorly differentiated SCC with aggressive invasiveness failed to do so. 
These results raise the possibility that the RANKL expression level in cell lines is repressed 
under culture conditions, and RANKL is a microenvironment-induced cytokine in vivo, of 
which expression is implicated in progression and biological malignancies of OSCC. 
 
Fig. 1. High RANKL expression in vivo. (A) mRNA levels in human OSCC specimens of 
tongue and gingival cancers and OSCC cell lines were evaluated by quantitative PCR. (B) 
Cells of OSCC cell lines were inoculated into nude mice and allowed to form tumor. The 
mRNA level in each sample was determined by quantitative PCR. 
4.2 Environment-dependent expression of RANKL 
To test the aforementioned hypothesis, several OSCC cell lines were inoculated into the 
masseter muscles of mice, one of the most established sites for an oral cancer orthotopic model 
(Cui et al., 2005; Nomura et al., 2007; Suda et al., 1997). As expected, RANKL expression was 
dramatically augmented at both mRNA and protein levels compared to those in cultured cells 
(Figure 1B). Moreover, the higher RANKL expression levels are observed in poorly 
differentiated, invasive SCC, in accordance with our clinicopathological findings. 
To assess the contribution of the oral environment to RANKL expression and subsequent 
tumor formation, HSC-3 cells, a OSCC cell line that formed tumors most efficiently in the 
orthotopic model, were also injected into the muscle of hindlimbs. This region was selected 
in analogy to the orthotopic site (intramuscular), as well as by its anatomical location far 
from the oral cavity. Tumors formed in the hindlimbs were significantly smaller than those 
in the masseter region (Figure 2A and B). In parallel with their tumor weight, RANKL could 
be detected in the masseter region tumors, but not in the hindlimb ones (Figure 2C). Thus, 
RANKL expression requires the orthotopic environment and correlates with tumor 
formation ability. Moreover, masseter region tumors, but not hindlimb ones, displayed the 
histological pattern of poorly differentiated squamous cell carcinoma (Figure 2D). 
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Fig. 2. Environment-dependent expression of RANKL. The OSCC cell line HSC-3 cells were 
injected into the masseter or hindlimb region of the mice. After 28 days, the formed tumors 
were weighted (A) and photographed (B). Expression levels of RANKL mRNA and protein 
in the tumors were analyzed by quantitative RT-PCR and immunoblotting, respectively (C). 
Histology of the tumors are also shown (D). 
4.3 RANKL expression accelerates tumor malignancy  
To further verify the role for RANKL in OSCC tumor formation, we established HSC-3 cell 
lines that stably express RANKL, and injected them into the mouse hindlimbs. RANKL-
expressing cells achieved efficient tumor formation in the hindlimbs, whereas control cells 
failed to form sizable tumors, similar to parental cells as described above (Figure 3A-C). 
These results together demonstrate that RANKL expression, which ordinarily depends on 
the oral environment, possesses the potential of inducing OSCC formation. By HE staining, 
it was revealed that RANKL-expressing, hindlimb-injected tumors exhibited more poorly 
differentiated and invasive characters than control tumors, consistent with the results 
observed in human specimens. 
4.4 RANKL induces epithelial-mesenchymal transition (EMT)  
Immunohistochemical analysis also revealed that E-cadherin was disappeared from the cell-
to-cell contact sites in tumors formed by RANKL-expressing cells, whereas control tumors 
displayed typical E-cadherin pattern (Figure 3D). Moreover, in response to E-cadherin 
disappearance from the plasma membrane, intense staining for N-cadherin was observed in 
the tumor cell cytoplasm in RANKL-expressing tumors. These findings raise the possibility 
that RANKL promotes loss of epithelial character, i.e. evokes EMT, a fundamental process 
during tumor development and progression (Yang J & Weinberg, 2008). 
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Fig. 3. OSCC tumor formation in hindlimb is facilitated by RANKL. Control (Ctrl) and RANKL-
expressing cells (RANKL) were injected into hindlimb muscles and, after 28 days, the tumors 
were weighed (B), and photographed (C). RANKL mRNA in the tumors was examined by RT-
PCR (A). The sections from the control (upper panel) and RANKL-expressing (lower) tumors 
were subjected to immunohistochemistry using an antibody against E-cadherin (D). mRNA 
levels of E-adhetin, N-cadherin, Slug, and ZEB1 were also analyzed by quantitative PCR (E). 
To test whether RANKL-expressing tumors in fact underwent EMT, we evaluated the 
expression levels of E-cadherin, N-cadherin, and several transcription factors implicated in 
EMT (Gotzmann et al., 2004). Indeed, expression of E-cadherin was significantly decreased 
in RANKL-expressing tumor cells. Accordingly, N-cadherin expression was dramatically 
upregulated in tumor tissues expressing RANKL. Therefore, these results confirmed that 
cadherin switching from E-cadherin to N-cadherin occurs in tumors expressing RANKL. Of 
transcription factors implicated in inducing EMT including Slug, Snail, Twist, and ZEB1, 
Slug and ZEB1 were upregulated in RANKL-expressing tumors (Figure 3E). However, we 
could note no differences in their expression in vitro. Moreover, notwithstanding the 
dramatic increment in tumor formation of RANKL-expressing cells in the hindlimbs, there 
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are no significant differences in in vitro proliferation, motility, and invasiveness between 
RANKL-expressing and control cell lines. Thus, RANKL functions, in addition to its 
expression, are also in a manner dependent on in vivo. 
4.5 Significance of RANKL as an in vivo-specific biomarker 
Beyond its cell autonomous function, RANKL possesses ability to promote tumor 
angiogenesis, to our surprise, in a manner independent of VEGF. RANKL-expressing tumors 
were grossly rich in blood vessels, and immunohistochemical analysis using an antibody 
against CD31, a well-established marker for endothelial cells, revealed that RANKL-expressing 
tumors harbor significantly more abundant tumor microvessels than control tumors. 
Interestingly, this angiogenic potency was hampered in the presence of osteoprotegerin (OPG), 
a RANKL decoy receptor that inhibits RANK-RANKL signaling, whereas neutralization of 
VEGF using an anti-VEGF antibody failed to do so. These results together demonstrate that 
RANKL promotes tumor angiogenesis in a manner dependent on its cognate receptor RANK, 
as reported previously (Kim et al., 2002), but independent of VEGF. 
One of the most serious clinical concerns accompanying OSCC is a high potential for local 
invasion, frequently targeting the adjacent bone. To conquer this, radical and surgical 
procedures have been enforced; however, the patients suffering from the deprivation of 
fundamental functions, including mastication and vocalization. Our findings may resolve 
this longstanding issue in OSCC; the recognition of RANKL and its relevant signaling as 
potential targets for conservative therapy will enable us to hamper the tumorigenesis and 
invasion by cutting the connection between OSCC and the tumor microenvironment. 
In addition to the conventional molecular targeted therapy (i.e. small compounds and 
humanized antibodies), RANKL may constitute a better candidate for cancer 
immunotherapy. Several tumor antigens such as cancer-testis antigens provide specific 
targets for cancer cells due to their restricted expression patterns (Maio et al., 2003; 
Nicholaou et al., 2006; Suri, 2006). However, in the case that these molecules are not 
essential for cancer cell survival, the cells can escape the challenge of the immune system by 
reducing the expression of the antigens. Since the expression of RANKL in response to the 
microenvironment is critical for OSCC progression, we strongly propose RANKL-RANK 
signaling as being central to the conservative, multimodal treatment for this disease. 
5. Conclusion 
In summary, we have overviewed biomarkers with a particular focus on ones, functions of 
which are relevant to OSCC development, progression and its malignant potential. As we 
disclose, in vivo “functional biomarkers” such as RANKL would be of particular importance 
for both diagnosis and therapy of this disease. 
The mechanism underlying the microenvironment-specific RANKL expression remains to 
be addressed. Given that the head and neck regions including the oral cavity are always 
challenged by every pathogen, the involvement of inflammatory responses might be 
indispensable for OSCC tumor initiation and progression (Allen et al., 2007; Choi & Myers, 
2008; Ferris & Grandis, 2007; Lin et al., 2002; Pries et al., 2006). In addition, this region is also 
abundant in a range of growth factors that contribute to malignant conversion of OSCC 
through activating diverse cancer-related signaling pathways (Yamada et al., 2008; Nagano 
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& Saya, 2004; Ponta et al., 2003; Todd & Wong, 1999). We thus explored RANKL-inducing 
agents from a wide range of growth factors as well as inflammatory cytokines; however, 
failed to identify it so far. CXCL13 can certainly upregulate RANKL (Yuvaraj et al., 2009), 
albeit less efficiently compared to the upregulation observed in vivo (unpublished result). In 
the future, we believe that through our observations and the unveiling of remaining 
associated issues, the establishment of more rational, potent anti-cancer therapy with 
consideration of the communication between cancer cells and their respective 
microenvironment will eventually be accomplished. 
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for cancers of the breast, colon, prostate, and melanoma during the same period. This book attempts to
provide a reference-friendly update on the etiologic/risk factors, current clinical diagnostic tools, management
philosophies, molecular biomarkers, and progression indicators of oral cancer.
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